Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status.

Chinese medical journal - 20 Apr 2026

Yang Xia, Wang Jin, An Huimin, He Yongtao, Gan Yi, Chen Qi, Liu Bo, Tang Wangyang, Fu Guoxiang, Jiang Zhinong

Abstract excerpt

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) is an emerging subtype with specific clinicopathological features and therapeutic strategies. However, limited studies are available on the molecular characteristics and prognosis of triple-negative breast cancer (TNBC). METHODS: This study was conducted using the clinicopathological and genomic data of 1006 TNBC patients, which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erb-b2 Receptor Tyrosine Kinases

Share to RYR2 gene

Share to Mutation

Share to Prognosis

Share to PTEN Phosphohydrolase

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41549542
DOI: 10.1097/CM9.0000000000003942
PMCID: PMC13090057

Genes

MUC17
PIK3CA
CSMD3
FAT3
PTEN
RYR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status.PMID 41549542Read ↗

Clinicopathological Characterization of HER2-Low-Expressing Triple-Negative Breast Cancer: Distinct Features From HER2-Zero Subtype.Semantic proximity Read ↗

Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysisSemantic proximity Read ↗

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read ↗

[Biological characteristics of triple negative breast cancer with low expression of HER2].Semantic proximity Read ↗

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesSemantic proximity Read ↗

Novel Immune Subtypes Identification of HER2 Positive Breast Cancer Based On Immunogenomic LandscapeSemantic proximity Read ↗

Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer.Semantic proximity Read ↗

Update on triple‐negative breast cancers – highlighting subtyping update and treatment implicationSemantic proximity Read ↗

Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort Study.Semantic proximity Read ↗

Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple negative breast cancerSemantic proximity Read ↗

Molecular subtypes and precision treatment of triple-negative breast cancerSemantic proximity Read ↗

Triple-negative breast cancer and the need for new therapeutic targets.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.